natgillin/translations-raw huggingface dataset:
Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval or QTc &gt; 500 ms.
Poznato prirođeno produljenje QTc intervala, ili bilo koje kliničko stanje za koje se zna da produljuje QTc interval ili QTc &gt; 500 ms.
Laboratories Merck Sharp &amp; Dohme- Chibret, Route de Marsat-RIOM, 63963 Clermont-Ferrand Cedex 9, France
Laboratories Merck Sharp &amp; Dohme- Chibret, Route de Marsat RIOM, 63963 Clermont Ferrand Cedex 9, Francuska
Laboratory abnormalities: laboratory abnormalities reported in these two trials and an ongoing follow-up study included elevations of ALT ( &gt; 5 x ULN) in 3%, of AST ( &gt; 5 x ULN) in 3%, of lipase (≥ 2.1 ULN) in 3% of the patients in the Zerit group.
Abnormalnosti u laboratorijskim nalazima: abnormalnosti u laboratorijskim nalazima opisana u navedena dva ispitivanja i studijama praćenja, a uključivala su porast ALT ( &gt; 5 x Gornje Granice Normale) u 3% bolesnika, ALT ( &gt; 5 x GGN) u 3% bolesnika i lipaze ( &gt; 2,1 GGN) u 3% bolesnika u skupini s lijekom Zerit.
Laboratory abnormalities: laboratory abnormalities reported in these two trials and an ongoing follow-up study included elevations of ALT ( &gt; 5 x ULN) in 3%, of AST ( &gt; 5 x ULN) in 3%, of lipase (≥ 2.1 ULN) in 3% of the patients in the Zerit group.
Abnormalnosti u laboratorijskim nalazima:abnormalnosti u laboratorijskim nalazima opisana u navedena dva ispitivanja i studijama praćenja, a uključivala su porast ALT ( &gt; 5 x Gornje Granice Normale) u 3% bolesnika, AST ( &gt; 5 x GGN) u 3% bolesnika i lipaze ( &gt; 2,1 GGN) u 3% bolesnika u skupini s lijekom Zerit.
Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disease, none had ALT elevations both &gt; 10 times ULN and &gt; 2 times baseline, and 1% of patients had ALT elevations &gt; 2 times baseline together with total bilirubin &gt; 2 times ULN and &gt; 2 times baseline.
Abnormalnosti laboratorijskih nalaza: do 48. tjedna niti jedan od bolesnika liječenih entekavirom s dekompenziranom bolešću jetre nije imao povišenja ALT &gt; 10 puta iznad GGN i &gt; 2 puta iznad početne vrijednosti, a 1% bolesnika imao je povišenja ALT &gt; 2 puta iznad početne vrijednosti s ukupnim bilirubinom &gt; 2 puta iznad GGN i &gt; 2 puta iznad početne vrijednosti.
Lack of early virologic response by treatment week 12 (detectable HCV-RNA with a &lt; 2 log10 reduction from baseline) was a criterion for discontinuation of treatment.
Izostanak ranog virološkog odgovora u 12. tjednu liječenja (mjerljiva HCV-RNK sa smanjenjem za &lt; 2 log10 od početne vrijednosti) bio je kriterij za obustavu liječenja.
Lack of early virologic response by Treatment week 12 (detectable HCV-RNA with a &lt; 2 log10 reduction from baseline) was a criterion for discontinuation of treatment.
Izostanak ranog virološkog odgovora u 12. tjednu liječenja (mjerljiva HCV-RNK uz smanjenje za &lt; 2 log10 od početne vrijednosti) bio je kriterij za obustavu liječenja.
Lacrimation increased (G3/4: &lt; 0.1%)
pojačano suzenje (G3/4: &lt; 0,1%)
Lacrimation increased (G3/4: &lt; 0.1%)
pojačano suzenje (G3/4: &lt; 0,1%);
Lactic acidosis is a serious reaction which may occur very rarely ( &lt; 1/10,000) (see section 4.4) and other reactions such as bone fracture, weight increase and oedema may occur commonly (≥ 1/100 to &lt; 1/10) (see section 4.4).
Laktacidoza je ozbiljna reakcija, koja vrlo rijetko ( &lt; 1/10 000) nastaje (vidjeti dio 4.4), dok se druge reakcije, kao što su prijelom kosti, povećanje tjelesne težine i edemi, često (≥ 1/100 i &lt; 1/10) pojavljuju (vidjeti dio 4.4).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 16 % - 36 % to serum albumin in in vitro studies).
U terapijskom rasponu doza, lamivudin ima linearnu farmakokinetiku i slabo se veže za albumin, glavni protein u plazmi ( &lt; 16 % - 36% za serumski albumin u ispitivanjima in vitro).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 16% - 36% to serum albumin in in vitro studies).
U terapijskom rasponu doziranja lamivudin ima linearnu farmakokinetiku i slabo se veže na albumin, glavni protein u plazmi ( &lt; 16 - 36% na serumski albumin u in vitro ispitivanjima).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 16% - 36% to serum albumin in in vitro studies).
U terapijskom rasponu doziranja lamivudin ima linearnu farmakokinetiku i slabo se veže na albumin, glavni protein u plazmi ( &lt; 16 – 36% na serumski albumin u in vitro ispitivanjima).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 36 % serum albumin in vitro).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza i ograničeno se veže za glavni protein u plazmi, albumin ( &lt; 36% albumina u serumu in vitro).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 16%-36% to serum albumin in in vitro studies).
U terapijskom rasponu doziranja lamivudin ima linearnu farmakokinetiku i slabo se veže na albumin, glavnu bjelančevinu u plazmi ( &lt; 16 - 36% na serumski albumin u in vitro ispitivanjima).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 36 % serum albumin in vitro).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza i ograničeno se veže za glavni protein u plazmi-albumin ( &lt; 36% serumskog albumina in vitro).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin ( &lt; 36% serum albumin in vitro).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza i ograničeno se veže za glavni protein u plazmi-albumin ( &lt; 36% serumskog albumina in vitro).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding in vitro ( &lt; 36%).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza i ograničeno se veže za proteine u plazmi in vitro ( &lt; 36%).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding in vitro ( &lt; 36%).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza te se u ograničenoj mjeri veže za proteine u plazmi in vitro ( &lt; 36%).
LAVENTAIR 55/22 micrograms also showed statistically significant improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 in the first study (inspiratory capacity: 237 ml and 316 ml respectively, residual volume: -466 ml and -643 ml respectively and functional residual capacity: -351 ml and -522 ml respectively; all p &lt; 0.001).
U prvom je ispitivanju LAVENTAIR od 55/22 mikrograma u 12. tjednu pokazao i statistički značajna poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 237 ml odnosno 316 ml, rezidualni volumen: -466 ml odnosno -643 ml i funkcionalni rezidualni kapacitet: -351 ml odnosno -522 ml; p &lt; 0,001 za sve).
LDH &gt; ULN
LDH &gt; GGN
LDL-C values &lt; 25 mg/dL ( &lt; 0.65 mmol/L)
Vrijednosti LDL-C &lt; 25 mg/dl ( &lt; 0,65 mmol/l)
Ledipasvir is &gt; 99.8% bound to human plasma proteins.
Ledipasvir je &gt; 99,8 % vezan za proteine ljudske plazme.
Leflunomide 20 mg/day was significantly superior to placebo in reducing the symptoms of arthritis in patients with psoriatic arthritis: the PsARC (Psoriatic Arthritis treatment Response Criteria) responders were 59 % in the leflunomide group and 29.7 % in the placebo group by 6 months (p &lt; 0.0001).
Leflunomid, 20 mg dnevno, pokazao se značajno boljim u smanjenju simptoma artritisa u odnosu na placebo u bolesnika sa psorijatičnim artritisom: od bolesnika koji su odgovorili na liječenje prema kriterijima PsARC (Psoriatic Arthritis Treatment Response Criteria) 59% bilo je u skupini liječenoj leflunomidom, a 29,7% u skupini koja je primala placebo u trajanju od 6 mjeseci (p &lt; 0,0001).
Lenalidomide has a potential for acute toxicity; minimum lethal doses after oral administration were &gt; 2000 mg/kg/day in rodents.
Lenalidomid ima potencijal za akutnu toksičnost; minimalne letalne doze nakon peroralne primjene bile su &gt; 2000 mg/kg/dan u glodavaca.
Lenalidomide is present in human semen ( &lt; 0.01% of the dose) after administration of 25 mg/day and the medicinal product is undetectable in semen of a healthy subject 3 days after stopping the substance (see section 4.4).
Lenalidomid je prisutan u ljudskoj spermi ( &lt; 0,01% doze) nakon primjene 25 mg/dan, a lijek se ne može otkriti u spermi zdravih ispitanika 3 dana nakon prestanka uzimanja lijeka (vidjetio dio 4.4).
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is &lt; 1.0 x 109/L, and/or platelet counts are &lt; 50 x 109/L.
Liječenje lenalidomidom ne smije se započeti ako je apsolutni broj neutrofila (ABN) &lt; 1,0 x 109/L i/ili broj trombocita &lt; 50 x 109/L.
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is &lt; 1.5 x 109/L, and/or platelet counts are &lt; 75 x 109/L.
Liječenje lenalidomidom ne smije se započeti ako je apsolutni broj neutrofila (ABN) &lt; 1,5 x 109/L i/ili broj trombocita &lt; 75 x 109/L.
Lenalidomide treatment must not be started if the ANC &lt; 1.0 x 109/L, and/or platelet counts &lt; 75 x 109/L or, dependent on bone marrow infiltration by plasma cells, platelet counts &lt; 30 x 109/L.
Liječenje lenalidomidom ne smije se započeti ako je ABN &lt; 1,0 x 109/L, i/ili broj trombocita &lt; 75 x 109/L ili je, ovisno o infiltraciji koštane srži plazma stanicama, broj trombocita &lt; 30 x 109/L.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to &lt; 480 ms or baseline.
Kada se produljenje QTc intervala poboljša na &lt; 480 ms ili vrati na početnu vrijednost, primjenu lenvatiniba treba nastaviti u smanjenoj dozi.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to &lt; 480 ms or baseline.
Lenvatinib treba nastaviti primjenjivati u sniženoj dozi kada se produljenje QTc intervala smanji na &lt; 480 ms ili na početnu vrijednost.
Less than 1% of subjects treated with ZEPATIER with or without ribavirin experienced ALT elevations &gt; 2.5 – 5 times the ULN during treatment; there were no treatment discontinuations due to these ALT elevations.
U manje od 1% ispitanika liječenih lijekom ZEPATIER s ribavirinom ili bez njega došlo je do povišenja vrijednosti ALT-a &gt; 2,5–5 puta iznad GGN-a tijekom liječenja; nijedan ispitanik nije prekinuo liječenje zbog tih povišenja ALT-a.
less than 28 weeks gestational age and/or body weight &lt; 1000g particularly when receiving parenteral nutrition with co-administration of medicinal products known to interfere with caffeine metabolism
manje od 28 tjedana gestacijske dobi i/ili tjelesne težine &lt; 1000 g osobito kad primaju parenteralnu prehranu kad se istovremeno primjenjuju lijekovi za koje se zna da utječu na metabolizam kofeina
Leukapheresis should be performed during the period when the ANC rises from &lt; 0.5 x 109/l to &gt; 5.0 x 109/l.
Leukaferezu treba raditi u vrijeme kad se apsolutni broj neutrofila poveća s &lt; 0,5 x 109/l na &gt; 5,0 x 109/l.
leukocyte count &lt; 3000/mm³
broj leukocita &lt; 3000/mm³
Leukocytosis (WBC &gt; 50 x 109/L) was observed in 41 % of donors and transient thrombocytopenia (platelets &lt; 100 x 109/L) following filgrastim and leukapheresis was observed in 35 % of donors.
Leukocitoza (leukociti &gt; 50 x 109/l) je uočena u 41 %, a prolazna trombocitopenija (trombociti &lt; 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze.
Leukocytosis (WBC &gt; 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (leukociti &gt; 50 x 109/l) je primijećena u 41 % davatelja, dok je prolazna trombocitopenija (trombociti &lt; 100 x 109/l) nakon filgrastima i leukafereze primijećena u 35 % davatelja (vidjeti dio 4.4).
Leukocytosis (WBC &gt; 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (L &gt; 50 x 109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti &lt; 100 x 109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja (vidjeti dio 4.4).
Leukocytosis (WBC &gt; 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (L &gt; 50 x109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti &lt; 100 x109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja (vidjeti dio 4.4).
Leukocytosis (WBC &gt; 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors.
Leukocitoza (L &gt; 50 x 109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti &lt; 100 x 109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja.
Leukocytosis (WBC &gt; 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors.
Leukocitoza (L &gt; 50 x109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti &lt; 100 x109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja..
Leukocytosis (white blood cell (WBC) &gt; 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets &lt; 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (broj bijelih krvnih stanica &gt; 50 x 109/l) je uočena u 41% davatelja, a prolazna trombocitopenija (trombociti &lt; 100 x 109/l) u 35% davatelja nakon primjene filgrastima i leukafereze (vidjeti dio 4.4).
Leukopenia was associated with a dose reduction for &lt; 0.5% of patients, and no patients permanently discontinued crizotinib treatment associated with leukopenia.
Leukopenija je bila povezana sa smanjenjem doze kod &lt; 0,5% bolesnika i niti u jednog bolesnika nije bilo trajnog prekida liječenja povezanog s leukopenijom.
Levels of VWF:RCo of &gt; 0.6 IU/ml (60 %) and of FVIII:C of &gt; 0.4 IU/ml (40 %) should be achieved.
Treba postići razine VWF:RCo od &gt; 0,6 IU/ml (60%) i FVIII:C od &gt; 0,4 IU/ml (40%).
Limited accumulation of irbesartan ( &lt; 20 %) is observed in plasma upon repeated once-daily dosing.
Ograničena akumulacija irbesartana ( &lt; 20%) zabilježena je u plazmi nakon primjene opetovanih doza jedanput na dan.
Limited accumulation of irbesartan ( &lt; 20%) is observed in plasma upon repeated once-daily dosing.
Ograničena akumulacija irbesartana ( &lt; 20%) zabilježena je u plazmi nakon primjene opetovanih doza jedanput na dan.
Limited accumulation of irbesartan ( &lt; 20%) is observed in plasma upon repeated once-daily dosing.
Ograničena akumulacija irbesartana ( &lt; 20%) zabilježena je u plazmi nakon primjene ponovljenih doza jedanput na dan.
Limited accumulation of irbesartan ( &lt; 20%) is observed in plasma upon repeated once-daily dosing.
Ograničeno nakupljanje irbesartana ( &lt; 20%) zabilježeno je u plazmi nakon primjene opetovanih doza jedanput na dan.
Limited accumulation of irbesartan ( &lt; 20%) is observed in plasma upon repeated once-daily dosing.
Ograničeno nakupljanje irbesartana ( &lt; 20%) zabilježeno je u plazmi nakon primjene ponovljenih doza jedanput na dan.
Limited clinical data suggest that in patients with a history of oral oestrogen-induced hypertriglyceridemia ( &gt; 5.6 mmol/l), raloxifene may be associated with a marked increase in serum triglycerides.
Ograničeni klinički podaci sugeriraju da primjena raloksifena može biti povezana sa značajnim porastom serumskih triglicerida u bolesnica koje su imale hipertrigliceridemiju ( 5,6 mmol/l) izazvanu oralnim estrogenima.
Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects ( &gt; 65 years) is similar to that in adults.
Ograničeni podaci ukazuju da je farmakokinetika pegfilgrastima u starijih ispitanika ( &gt; 65 godina) slična kao i u odraslih.
Limited data is available in patients &lt; 50 kg (see section 5.2).
Podaci za bolesnike &lt; 50 kg su ograničeni (vidjeti dio 5.2).
Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts &lt; 200/µl (see section 4.4).
Ograničeni su podaci o sigurnosti (N=25) za bolesnike s istodobnom infekcijom u kojih je broj CD4+ stanica &lt; 200/µl (vidjeti dio 4.4).
Limited safety data (N= 25) are available in co-infected patients with CD4+ cell counts &lt; 200/µl (see section 4.4).
Dostupni su ograničeni podaci o sigurnosti (N=25) za bolesnike s istodobnom infekcijom u kojih je broj CD4+ stanica bio &lt; 200/μl (vidjeti dio 4.4).
Limited safety data are available from a paediatric study (NV20911, n=18) in which the safety of saquinavir hard capsules (50 mg/kg bid, not to exceed 1000 mg bid) used in combination with low dose ritonavir oral solution (3 mg/kg bid for body weight from 5 to &lt; 15 kg, 2.5 mg/kg bid for body weight from 15 to 40 kg and 100 mg bid for body weight &gt; 40 kg) has been studied in paediatric patients aged 4 months to 6 years old.
Dostupni su ograničeni podaci o sigurnosti iz pedijatrijskog ispitivanja (NV20911, n=18) u kojem je u pedijatrijskih bolesnika u dobi od 4 mjeseca do 6 godina ispitivana sigurnost primjene tvrdih kapsula sakvinavira (50 mg/kg dvaput na dan, ali ne više od 1000 mg dvaput na dan) u kombinaciji s niskom dozom oralne otopine ritonavira (3 mg/kg dvaput na dan za tjelesnu težinu od 5 do &lt; 15 kg, 2,5 mg/kg za tjelesnu težinu od 15 do 40 kg i 100 mg dvaput na dan za tjelesnu težinu &gt; 40 kg).
Limited safety data are available from a paediatric study (NV20911, n=18) in which the safety of saquinavir hard capsules (50 mg/kg bid, not to exceed 1000 mg bid) used in combination with low dose ritonavir oral solution (3 mg/kg bid for body weight from 5 to &lt; 15 kg, 2.5 mg/kg bid for body weight from 15 to 40 kg and 100 mg bid for body weight &gt; 40 kg) has been studied in paediatric patients aged 4 months to 6 years old.
Dostupni su ograničeni podaci o sigurnosti iz pedijatrijskog ispitivanja (NV20911, n=18) u kojem je u pedijatrijskih bolesnika u dobi od četiri mjeseca do šest godina ispitivana sigurnost primjene tvrdih kapsula sakvinavira (50 mg/kg dvaput na dan, ali ne više od 1000 mg dvaput na dan) u kombinaciji s niskom dozom oralne otopine ritonavira (3 mg/kg dvaput na dan za tjelesnu težinu od 5 do &lt; 15 kg, 2,5 mg/kg za tjelesnu težinu od 15 do 40 kg i 100 mg dvaput na dan za tjelesnu težinu &gt; 40 kg).
Limited safety data are available in co-infected patients with CD4+ cell counts &lt; 200/µl.
bolesnike istodobno zaražene HIV-om i HCV-om s brojem CD4+ stanica &lt; 200/µl, dostupni su ograničeni podaci o sigurnosti.
Limited safety data on Pravafenix is available in patients &gt; 75 years of age and care should be exercised.
Dostupni su ograničeni podaci o sigurnosti Pravafenixa u bolesnika &gt; 75 godina starosti, stoga je nužan oprez.
Linagliptin also provided significant improvements in fasting plasma glucose (FPG), and a greater proportion of patients achieved a target HbA1c of &lt; 7.0%, compared to placebo.
Linagliptin je također pokazao značajna poboljšanja glukoze u plazmi natašte, kao i veći broj bolesnika koji su postigli ciljni HbA1c od &lt; 7,0%, u usporedbi s placebom.
Linagliptin also showed significant improvements in patients achieving a target HbA1c of &lt; 7.0% (31.2% on linagliptin versus 9.2% on placebo), and also for fasting plasma glucose (FPG) with -12.7 mg/dl reduction compared to placebo.
Linagliptin je također pokazao značajna poboljšanja u bolesnika koji su postigli ciljni HbA1c od &lt; 7,0% (31,2% u skupini na linagliptinu naspram 9,2% u skupini na placebu) i također za razinu glukoze u plazmi natašte (FPG) sa smanjenjem od -12,7 mg/dl u usporedbi sa skupinom na placebu.
Linagliptin binds selectively to DPP-4 and exhibits a &gt; 10,000 fold selectivity versus DPP-8 or DPP-9 activity in vitro.
Linagliptin se selektivno veže na DPP-4 i pokazuje &gt; 10 000 puta veću selektivnost u odnosu na aktivnost DPP-8 ili DPP-9 in vitro.
Lipodystrophy (thickening or pitting of the skin) is uncommon ( 1/1,000 to &lt; 1/100).
Lipodistrofija (zadebljanja ili ulegnuća na koži) je manje česta (≥ 1/1000 i &lt; 1/100).
Lipodystrophy at the injection site is uncommon (1/1,000 to &lt; 1/100).
Lipodistrofija na mjestu injekcije je manje česta nuspojava (1/1000 i &lt; 1/100).
Liraglutide exposure was lowered by 33%, 14%, 27% and 28%, respectively, in subjects with mild (creatinine clearance, CrCl 50–80 mL/min), moderate (CrCl 30–50 mL/min), and severe (CrCl &lt; 30 mL/min) renal impairment and in end-stage renal disease requiring dialysis.
Izloženost liraglutidu bila je smanjena za 33%, 14%, 27% i 28% u ispitanika s blažim (klirens kreatinina, CrCl 50-80 ml/min), umjerenim (CrCl 30-50 ml/min) i teškim (CrCl &lt; 30 ml/min) oštećenjem bubrega, odnosno u završnom stadiju bolesti bubrega gdje je potrebna dijaliza.
Liraglutide in combination therapy, for 26 weeks, with metformin, glimepiride or metformin and rosiglitazone resulted in statistically significant (p &lt; 0.0001) and sustained reductions in HbA1c compared with patients receiving placebo (Table 2).
Liraglutid je tijekom 26-tjednog kombiniranog liječenja s metforminom, glimepiridom ili metforminom i roziglitazonom doveo do statistički značajnog (p &lt; 0,0001) i održanog smanjenja HbA1c u usporedbi s bolesnicima koji su primali placebo (Tablica 2 ).
Liraglutide is extensively bound to plasma proteins ( &gt; 98%).
Liraglutid se u velikoj mjeri veže za proteine plazme ( &gt; 98%).
Liver effects were seen at doses above ( &gt; 3) human exposure and have generally been shown to be reversible.
Učinci na jetru opaženi su pri dozama većima ( &gt; 3) od izloženosti ljudi i općenito su se pokazali reverzibilnima.
Liver transplant recipients: the safety and efficacy of entecavir 1 mg once daily were assessed in a single-arm study in 65 patients who received a liver transplant for complications of chronic HBV infection and had HBV DNA &lt; 172 IU/ml (approximately 1000 copies/ml) at the time of transplant.
Primatelji transplantata jetre: Sigurnost i djelotvornost entekavira u dozi od 1 mg jednom dnevno bile su procijenjene u ispitivanju na jednoj skupini od 65 bolesnika koji su primili transplantat jetre zbog komplikacija kronične infekcije HBV-om i imali HBV DNK &lt; 172 IU/ml (približno 1000 kopija/ml) u vrijeme transplantacije.
Lixisenatide provided significant improvements in HbA1c (-0.64% change compared to placebo; 95% CI: -0.810% to -0.464%; p &lt; 0.0001), from a mean baseline HbA1c of 8.0%.
Liksisenatid je doveo do značajnog poboljšanja HbA1c (-0,64% promjene u usporedbi s placebom; 95% IP: -0,810% do -0,464%; p &lt; 0,0001) u odnosu na srednje vrijednosti HbA1c od 8,0% na početku.
load ( &lt; 50 HIV-1 RNA
opterećenje ( &lt; 50 HIV-1 RNK
Local allergy in patients is common (1/100 to &lt; 1/10).
Lokalna alergijska reakcija je česta nuspojava (1/100 i &lt; 1/10).
Local allergy is common ( 1/100 to &lt; 1/10).
Lokalna alergijska reakcija je česta (≥ 1/100 i &lt; 1/10).